Elligo Joins Efforts To Expand COVID-19 Risk Screening, Testing
Elligo Health Research, a healthcare-enabling research organization, is working with Verily to support the Project Baseline COVID-19 Program. The program is a collaboration with the California Governor’s office, federal, state and local public health authorities, to expand COVID-19 risk screening and testing. Elligo is one of the few companies to project-manage and staff drive-by COVID-19 test sites with three initial sample-collection sites that launched Monday, March 16 in San Mateo County and Santa Clara County. Additional locations are expected in the coming weeks.
Elligo is also providing a full spectrum of solutions to help manage COVID-19 testing efforts on-site and off-site, including access to staff and partnerships with national labs to support needs once samples are collected; site-specific recommendations on workflow, standard operating procedures, and protocols; and a support team for current medical staff, among other services.
For more, click here.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
